Editing Sumatriptan (section)

==Adverse effects==
Overdose of sumatriptan can cause [[sulfhemoglobinemia]], a rare condition in which the blood changes from red to green, due to the integration of [[sulfur]] into the [[hemoglobin]] molecule. If sumatriptan is discontinued, the condition reverses within a few weeks.<ref>{{cite news |date=8 June 2007 |title=Patient bleeds dark green blood |url=http://news.bbc.co.uk/2/hi/health/6733203.stm |url-status=live |archive-url=https://web.archive.org/web/20100805042210/http://news.bbc.co.uk/2/hi/health/6733203.stm |archive-date=5 August 2010 |access-date=6 March 2010 |work=BBC News |df=dmy-all}}</ref>

Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included [[coronary artery vasospasm]], transient myocardial ischemia, [[myocardial infarction]], [[ventricular tachycardia]], and [[ventricular fibrillation]].<ref>{{cite journal | vauthors = Kelly KM | title = Cardiac arrest following use of sumatriptan | journal = Neurology | volume = 45 | issue = 6 | pages = 1211–1213 | date = June 1995 | pmid = 7783891 | doi = 10.1212/wnl.45.6.1211 | s2cid = 35168945 }}</ref> There are reports of [[Takotsubo cardiomyopathy]] and transient [[amnesia]] after sumatriptan use.<ref>{{Cite journal | vauthors = Chohan A |date=2023-03-07 |title=Sumatriptan-Induced Takotsubo Cardiomyopathy  |url=https://linkinghub.elsevier.com/retrieve/pii/S0735109723039426 |journal=Journal of the American College of Cardiology |series=ACC.23 |volume=81 |issue=8, Supplement |pages=3498 |doi=10.1016/S0735-1097(23)03942-6 |issn=0735-1097}}</ref>

The most common side effects<ref>{{cite web |url = https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4180b_09_05_Imitrex%20label%20tablet%2012-04%20Sponsor.pdfsumatriptan |title = Tablets |website = fda.gov |access-date = 19 February 2018 }}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref> reported by at least 2% of patients in controlled trials of sumatriptan (25-, 50-, and 100-mg tablets) for migraine are atypical sensations ([[paresthesias|paresthesia]] and warm/cold sensations) reported by 4% in the placebo group and 5–6% in the sumatriptan groups, pain and other pressure sensations (including [[chest pain]]) reported by 4% in the placebo group and 6–8% in the sumatriptan groups, neurological events ([[vertigo]]) reported by less than 1% in the placebo group and less than 1% to 2% in the sumatriptan groups. [[Malaise]]/[[fatigue]] occurred in less than 1% of the placebo group and 2–3% of the sumatriptan groups. [[Sleep disorder|Sleep disturbance]] occurred in less than 1% in the placebo group to 2% in the sumatriptan group.

Sumatriptan has a low [[abuse potential]];<ref>{{cite journal | vauthors = Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR | title = Psychoactivity and abuse potential of sumatriptan | journal = Clinical Pharmacology and Therapeutics | volume = 52 | issue = 6 | pages = 635–642 | date = December 1992 | pmid = 1333934 | doi = 10.1038/clpt.1992.202 }}</ref> however overuse is associated with [[medication overuse headache]].<ref>{{Cite web |title=TGA eBS - Product and Consumer Medicine Information |url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=pi&q=sumatriptan |access-date=2025-03-03 |website=www.ebs.tga.gov.au}}</ref> Moreover, prolonged sumatriptan use is associated with pronociceptive effects, resulting in [[allodynia]]. This effect's association with medication overuse headache, however, is controversial, due to the fact that animal-model studies are not consistent with typical presentation of this disorder.<ref>{{Cite journal | vauthors = Chiarugi A, Buonvicino D |date=2025-01-01 |title=Critical reflections on medication overuse headache in patients with migraine: An unsolved riddle in nociception |journal=Neurobiology of Pain |volume=17 |pages=100179 |doi=10.1016/j.ynpai.2025.100179 |pmid=40040782 |issn=2452-073X|pmc=11876746 }}</ref>